文献速递腹部胸部CT

结肠癌患者分期胸部CT的诊断率与假转诊率

Diagnostic Yield and False-Referral Rate of Staging Chest CT in Patients with Colon Cancer.
PubMed 文献 · Radiology · 2018-08-07

本回顾性研究纳入1743例结肠癌患者,按增强腹部CT临床分期分层,评估增强胸部CT检测胸部转移的诊断率与假转诊率。临床0/I期诊断率为0%,II、III、IV期分别为1.3%、4.4%、43.3%;各期假转诊率无显著差异。

要点

  • 临床0/I期胸部CT诊断率为0%,未发现胸部转移。
  • 临床II、III、IV期胸部CT诊断率分别为1.3%、4.4%、43.3%。
  • 临床分期与假转诊率之间无显著关联。

核心结论

  • 临床0/I期分期增强胸部CT检测胸部转移的诊断率为0%;临床II、III、IV期胸部CT作为基线检查有助于检出胸部转移并提供治愈性转移灶切除的可能性;临床分期与假转诊率无显著关联。

研究设计与样本

  • 回顾性研究,纳入1743例结肠癌患者(平均年龄63.4岁,范围18-96岁),以增强腹部CT临床分期分层,评估增强胸部CT检测胸部转移的诊断率与假转诊率。

诊断标准与关键数值

  • 临床0/I期诊断率0%(95%CI:0%,0.8%),假转诊率5.7%(95%CI:3.8%,8.2%),隐匿性转移比例0%(95%CI:0%,0.8%),肺转移灶切除比例0%(474例中无1例;95%CI:0%,0.8%)。
  • 临床II期诊断率1.3%(95%CI:0.4%,3.3%),假转诊率2.9%(95%CI:1.3%,5.5%),隐匿性转移比例3.3%(95%CI:1.6%,5.9%)。
  • 临床III期诊断率4.4%(95%CI:3.0%,6.1%),假转诊率6.7%(95%CI:5.0%,8.8%),隐匿性转移比例1.5%(95%CI:0.8%,2.7%)。
  • 临床IV期诊断率43.3%(95%CI:36.8%,49.9%),假转诊率6.1%(95%CI:3.4%,10.0%),隐匿性转移比例6.1%(95%CI:3.4%,10.0%)。

临床应用与阅片要点

  • 临床0/I期结肠癌患者增强胸部CT未检出胸部转移,诊断率为0%。
  • 临床II、III、IV期增强胸部CT作为基线检查有助于检出胸部转移,并可能为治愈性转移灶切除提供机会。
  • 临床分期与假转诊率之间无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To measure the diagnostic yield and false-referral rate (FRR) of staging contrast material-enhanced chest CT based on the clinical stage from contrast-enhanced abdominal CT in patients with colon cancer. Materials and Methods This retrospective study included 1743 patients (mean age, 63.4 years; range, 18-96 years) with a diagnosis of colon cancer. The primary outcomes were diagnostic yield and FRR of contrast-enhanced chest CT in the detection of thoracic metastasis. The proportions of patients with occult thoracic metastasis and those undergoing pulmonary metastasectomy for true-positive metastases were key secondary outcomes. The outcomes were stratified according to clinical stage at contrast-enhanced abdominal CT. Results The diagnostic yields in clinical stage 0/I, cII, cIII, and cIV were 0% (95% confidence interval [CI]: 0%, 0.8%), 1.3% (95% CI: 0.4%, 3.3%), 4.4% (95% CI: 3.0%, 6.1%), and 43.3% (95% CI: 36.8%, 49.9%), respectively. The corresponding FRRs were 5.7% (95% CI: 3.8%, 8.2%), 2.9% (95% CI: 1.3%, 5.5%), 6.7% (95% CI: 5.0%, 8.8%), and 6.1% (95% CI: 3.4%, 10.0%), respectively. The proportions of patients with occult metastasis were 0% (95% CI: 0%, 0.8%), 3.3% (95% CI: 1.6%, 5.9%), 1.5% (95% CI: 0.8%, 2.7%), and 6.1% (95% CI: 3.4%, 10.0%), respectively. The proportion of patients who underwent pulmonary metastasectomy was 0% (none of 474; 95% CI: 0%, 0.8%) for clinical stage 0/I tumors. Conclusion In clinical stages 0 and I, the diagnostic yield of staging contrast-enhanced chest CT in detecting thoracic metastasis was zero. For clinical stages II, III, and IV, contrast-enhanced chest CT as a baseline examination was helpful for the detection of thoracic metastasis and allowed for the possibility of a curative metastasectomy. There was no significant association between clinical stage and false-referral rate. © RSNA, 2018 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lee KH, Park JH, Kim YH, et al. Diagnostic Yield and False-Referral Rate of Staging Chest CT in Patients with Colon Cancer. Radiology. 2018. PMID: 30084734. doi:10.1148/radiol.2018180009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。